protein tyrosine phosphatase non-receptor type 4Genealiases: MEG · PTPMEG · PTPMEG1
Q-omics provides the consensus-scored PTPN4 profile across patient tissues and cancer cell-line models. PTPN4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PTPN4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PTPN4 RNA expression shows 21,872 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where PTPN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN4 survival associations across molecular data types. PTPN4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN4 RNA expression–survival associations across cancer types. High PTPN4 expression shows unfavorable associations in ACC, but favorable associations in KIRC, OV, SKCM, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PTPN4 RNA expression.
This table summarizes PTPN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PTPN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN4 shows lower tumor expression in KIRC, THCA, KICH, KIRP and BRCA and higher tumor expression in HNSC. The KIRC box plot shows higher PTPN4 RNA expression in normal versus tumor tissue (log2 FC = −0.920, t-test p < 0.001).
This table shows molecular features associated with PTPN4 in patient tissues and cancer cell lines. In patient samples, PTPN4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
